DELIVER G was a retrospective pre-post study of 271 adult patients with type 2 diabetes receiving GLP-1 RA therapy who were insulin-naive prior to subsequent treatment intensification with Gla-300. DELIVER G included data from a large US EMR data source (IBM® Explorys).1
Patient Identification
Eligible Patients1:
- Adults with a diagnosis of T2DM
- Diagnosis of T2DM
- Receiving GLP-1 RA therapy that was intensified by adding Gla-300 between March 1, 2015 and September 30, 2019
- Insulin–naive prior to treatment intensification
- ≥12 months’ pre-Gla-300 data and ≥6 months of follow-up data available
- HbA1c 3% to 15%, recorded in the 6 months prior to intensification with Gla-300 and 3- to 9-months after intensification
Adding Toujeo® U-300 (insulin glargine) injection 300 Units/mL to GLP-1 RA in insulin-naive patients with T2DM
DELIVER-G pre-post study: a retrospective analysis of US EMRs1
Reduction in mean A1C observed1
Proportion of patients who achieved A1C goal of <7%1
Overall hypoglycemia event rates were comparable1
.svg)
.svg)
Observed in a retrospective analysis of US EMRs following treatment intensification with Toujeo in adults inadequately controlled on GLP-1 RA ± OAD(s) therapy who had ≥6 months of follow-up data (N=271).1*
Hypoglycemia is the most common adverse event associated with insulin-containing therapies.
DELIVER G pre-post study: A retrospective analysis of US EMRs
Pre - post study is a measure of a single study outcomes before and after an intervention.
Limitations1:
- Results should be interpreted with caution because of the retrospective pre-post design without a control or comparator arm and the relatively short follow-up (6 months)
- Hypoglycemia may have been underreported, as only the clinically significant events were likely to have been captured (eg, no SMBG or CGM data)
- EMR database analysis as a potential for selection bias that cannot be controlled, as well as EMR data-capture challenges (eg, coding errors, no dosing data)
- Patients were mainly from the Northwest and Southern US states and therefore may not be representative of the US national landscape
- Sanofi-sponsored study
*Follow-up period ≥6 months included GLP-1 RA + Toujeo (N=271).1
Important Safety Information
†Eligibility Restrictions & Offer Terms for Your Patients:
Sanofi Insulins Co-pay Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Sanofi Insulins Co-pay Savings Program at (866) 255-8661 (8:00 am-8:00 pm EST, Monday-Friday).
Insulins Valyou Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is only valid for those who are uninsured or those who are insured by a prescription plan but are not using such insurance and will be paying the full retail price for the medication. Void where prohibited by law. The Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. You may not submit claims for reimbursement to any third-party payor, including any government healthcare plan (e.g., Medicare, Medicaid, DOD, VA, TRICARE) or similar federal or state programs for Sanofi Insulin prescriptions when using this Program. You may not seek to have your out-of-pocket costs or the full retail price of the Sanofi Insulin count toward your deductible, true-out-of-pocket (TrOOP), maximum out-of-pocket (MOOP), or any other out-of-pocket caps associated with any insurance coverage. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Insulins Valyou Savings Program at (833) 813-0190 (8:00 am-8:00 pm EST, Monday-Friday).
A1C, glycated hemoglobin; CGM, continuous glucose monitoring; EMR, electronic medical record; GLP-1, glucagon-like peptide-1; OAD, oral antidiabetic drug; PPPY, per patient per year; RA, receptor agonist; SMBG, self-monitoring of blood glucose; T2DM, type 2 diabetes mellitus.
Reference:
1. Data on file. Clinical Study Report. CS_00375/CEF0057. Sanofi US 2022.
